A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy

Introduction: Clinical trials confirmed the beneficial effects of adding pertuzumab (P) to the combination of trastuzumab-chemotherapy (TC) in the (neo)adjuvant setting of high-risk HER2-positive early breast cancer (HER2+BC). We evaluated the clinical, economic and societal impact of adding pertuzu...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alberto Zambelli, Marina Cazzaniga, Nicla La Verde, Elisabetta Munzone, Ippazio Cosimo Antonazzo, Lorenzo Giovanni Mantovani, Serena Di Cosimo, Anna Mancuso, Daniele Generali, Paolo Angelo Cortesi
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-10-01
Col·lecció:	Breast
Matèries:	Breast cancer Pertuzumab Neoadjuvant Italy Cost-consequence analysis
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S0960977623005404
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!